Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening.

Häusler SF, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S, Krockenberger M, Engel JB, Hönig A, Scheffler M, Dietl J, Wischhusen J.

Br J Cancer. 2010 Aug 24;103(5):693-700. doi: 10.1038/sj.bjc.6605833. Epub 2010 Aug 3.


A specific miRNA signature in the peripheral blood of glioblastoma patients.

Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, Eisele G, Weller M, Keller A.

J Neurochem. 2011 Aug;118(3):449-57. doi: 10.1111/j.1471-4159.2011.07307.x. Epub 2011 Jun 17.


Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patients.

Chung YW, Bae HS, Song JY, Lee JK, Lee NW, Kim T, Lee KW.

Int J Gynecol Cancer. 2013 May;23(4):673-9. doi: 10.1097/IGC.0b013e31828c166d.


Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection.

Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A, Hein A, Bayer CM, Bani MR, Richter S, Adamietz BR, Wenkel E, Rauh C, Beckmann MW, Fasching PA.

PLoS One. 2012;7(1):e29770. doi: 10.1371/journal.pone.0029770. Epub 2012 Jan 5.


Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle.

Ahmed FE, Ahmed NC, Vos PW, Bonnerup C, Atkins JN, Casey M, Nuovo GJ, Naziri W, Wiley JE, Mota H, Allison RR.

Cancer Genomics Proteomics. 2013 May-Jun;10(3):93-113.


Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study.

Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS, Ditzel HJ.

Mol Oncol. 2014 Jul;8(5):874-83. doi: 10.1016/j.molonc.2014.03.002. Epub 2014 Mar 16.


Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer.

Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, Hao Q, Hu Z, Zhang W, Chen K.

PLoS One. 2013 Nov 1;8(11):e77853. doi: 10.1371/journal.pone.0077853. eCollection 2013.


Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer.

Suryawanshi S, Vlad AM, Lin HM, Mantia-Smaldone G, Laskey R, Lee M, Lin Y, Donnellan N, Klein-Patel M, Lee T, Mansuria S, Elishaev E, Budiu R, Edwards RP, Huang X.

Clin Cancer Res. 2013 Mar 1;19(5):1213-24. doi: 10.1158/1078-0432.CCR-12-2726. Epub 2013 Jan 29.


What makes a blood cell based miRNA expression pattern disease specific?--a miRNome analysis of blood cell subsets in lung cancer patients and healthy controls.

Leidinger P, Backes C, Dahmke IN, Galata V, Huwer H, Stehle I, Bals R, Keller A, Meese E.

Oncotarget. 2014 Oct 15;5(19):9484-97.


Circulating microRNAs as specific biomarkers for breast cancer detection.

Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES, Pang R, Chua D, Chu KM, Law WL, Law SY, Poon RT, Kwong A.

PLoS One. 2013;8(1):e53141. doi: 10.1371/journal.pone.0053141. Epub 2013 Jan 3.


Identification of a circulating microRNA signature for colorectal cancer detection.

Wang J, Huang SK, Zhao M, Yang M, Zhong JL, Gu YY, Peng H, Che YQ, Huang CZ.

PLoS One. 2014 Apr 7;9(4):e87451. doi: 10.1371/journal.pone.0087451. eCollection 2014.


Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease.

Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ.

Oncologist. 2010;15(7):673-82. doi: 10.1634/theoncologist.2010-0103. Epub 2010 Jun 24.


Circulating exosomal microRNAs as biomarkers of colon cancer.

Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H, Sonoda H, Watanabe M, Nakagama H, Yokota J, Kohno T, Tsuchiya N.

PLoS One. 2014 Apr 4;9(4):e92921. doi: 10.1371/journal.pone.0092921. eCollection 2014.


Decreased serum miR-181a is a potential new tool for breast cancer screening.

Guo LJ, Zhang QY.

Int J Mol Med. 2012 Sep;30(3):680-6. doi: 10.3892/ijmm.2012.1021. Epub 2012 Jun 11.


Plasma microRNA profiles for bladder cancer detection.

Adam L, Wszolek MF, Liu CG, Jing W, Diao L, Zien A, Zhang JD, Jackson D, Dinney CP.

Urol Oncol. 2013 Nov;31(8):1701-8. doi: 10.1016/j.urolonc.2012.06.010. Epub 2012 Aug 3.


Differential microRNA expression by Solexa sequencing in the sera of ovarian cancer patients.

Ji T, Zheng ZG, Wang FM, Xu LJ, Li LF, Cheng QH, Guo JF, Ding XF.

Asian Pac J Cancer Prev. 2014;15(4):1739-43.


A novel serum microRNA panel to discriminate benign from malignant ovarian disease.

Langhe R, Norris L, Saadeh FA, Blackshields G, Varley R, Harrison A, Gleeson N, Spillane C, Martin C, O'Donnell DM, D'Arcy T, O'Leary J, O'Toole S.

Cancer Lett. 2015 Jan 28;356(2 Pt B):628-36. doi: 10.1016/j.canlet.2014.10.010. Epub 2014 Oct 16.


Identification and validation of miRNAs as endogenous controls for RQ-PCR in blood specimens for breast cancer studies.

McDermott AM, Kerin MJ, Miller N.

PLoS One. 2013 Dec 31;8(12):e83718. doi: 10.1371/journal.pone.0083718. eCollection 2013.


Serum circulating microRNA profiling for identification of potential breast cancer biomarkers.

Mar-Aguilar F, Mendoza-Ramírez JA, Malagón-Santiago I, Espino-Silva PK, Santuario-Facio SK, Ruiz-Flores P, Rodríguez-Padilla C, Reséndez-Pérez D.

Dis Markers. 2013;34(3):163-9. doi: 10.3233/DMA-120957.


Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.

Vilming Elgaaen B, Olstad OK, Haug KB, Brusletto B, Sandvik L, Staff AC, Gautvik KM, Davidson B.

BMC Cancer. 2014 Feb 11;14:80. doi: 10.1186/1471-2407-14-80.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk